BNTXBioNTech SESigning up patients
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 736 (planned)
- Started
- Apr 22, 2026
- Main results expected
- Feb 2031
- Fully finished
- Feb 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
rPFS assessed by BICR
Measured over: From randomization to end of study, i.e., up to 58 months
OS
Measured over: From randomization to end of study, i.e., up to 58 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07365995 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC